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(H1N1) became resistant to both os-
eltamivir and amantadine in a short 
span of 1 month. Oseltamivir-resistant 
A/Brisbane/59/2007-like clade 2B vi-
rus that had reassorted with A/Hong 
Kong/2652/2006-like clade 2C virus 
had apparently spread in the commu-
nity and to other regions of the world. 
The possibility of reassortment with 
pandemic (H1N1) 2009 virus is a ma-
jor concern. Resistance to oseltamivir 
of pandemic (H1N1) 2009 virus will 
compromise its use in treatment and 
render the billion-dose stockpile use-
less. Although the recently detected 
oseltamivir-resistant pandemic (H1N1) 
2009 virus in Hong Kong was not a re-
assortant virus (4,5), we will continue 
to closely monitor antiviral drug resis-
tance among circulating viruses, includ-
ing pandemic (H1N1) 2009 virus and 
seasonal inﬂ  uenza virus A (H1N1), as 
well as inﬂ  uenza A (H3N2) viruses, to 
track how antiviral resistance evolves.
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Pandemic (H1N1) 
2009 Reinfection, 
Chile
To the Editor: Since March 
2009, inﬂ  uenza A pandemic (H1N1) 
2009 has spread worldwide (1), and 
in South America, Chile was 1 of the 
countries most affected by the pan-
demic, with 21.4 cases among every 
1,000 persons. Treatment guidelines 
in Chile recommended antiviral drug 
treatment with oseltamivir or zana-
mivir for 5 days for all patients with 
conﬁ  rmed or suspected virus subtype 
H1N1 infection (2). In persons with 
seasonal inﬂ  uenza, speciﬁ  c antibody 
responses reach peak titers by 4 weeks 
after infection and confer protection 
against the infecting strain and close-
ly related strains (3). Reinfection is 
rarely seen in nonpandemic inﬂ  uenza 
A. We report on 3 patients with con-
ﬁ  rmed inﬂ  uenza A pandemic (H1N1) 
2009 reinfection after successful treat-
ment with oseltamivir.
Patient 1, a healthy 14-year-old 
girl, had fever, sore throat, and nasal 
congestion on clinical examination. 
Pandemic (H1N1) 2009 infection 
was diagnosed by viral culture and 
conﬁ  rmed by PCR speciﬁ  c for sub-
type H1N1 (LightMix Kit Inf A swine 
H1; TIB MOLBIOL, Berlin, Germa-
ny, for Roche Diagnostic, Indianapo-
lis, IN, Light Cycler 2.0 instrument). 
The patient received oseltamivir, and 
symptoms resolved 48 hours after 
treatment. Twenty days later, fever, 
muscle aches, and vomiting devel-
oped in the patient. Inﬂ  uenza A virus 
was isolated by viral culture. The pa-
tient received a preliminary diagnosis 
of seasonal inﬂ  uenza and was treated 
with amantadine. She recovered from 
the infection before PCR results con-
ﬁ   rmed it was caused by pandemic 
(H1N1) 2009 virus. 
Patient 2, a 62-year-old woman, 
experienced a high fever, cough, and 
nasal congestion during a prolonged 
hospitalization for bowel resection 
after intestinal ischemia. Pandemic 
(H1N1) 2009 was conﬁ  rmed by PCR 
and viral culture. Oseltamivir was 
administered 5 days after the onset 
of symptoms, and the symptoms re-
solved within the following 5 days. 
The patient had a new episode of fe-
ver, productive cough, and bronchial 
obstruction 2 weeks later while still 
hospitalized. Culture results were 
positive for inﬂ  uenza, and PCR results 
were positive for pandemic (H1N1) 
2009. The patient was again treated 
with oseltamivir, and PCR results 
were negative for inﬂ  uenza after 48 
hours of antiviral treatment.
Patient 3, a previously healthy 
38-year-old man, underwent mitral 
and aortic valve replacement while 
hospitalized for acute mitral and aor-
tic endocarditis due to Staphylococcus 
aureus. Eleven days after surgery, he 
had a sore throat, nasal congestion, 
cough, and low-grade fever. PCR test 
results were positive for pandemic 
(H1N1) 2009. The patient received 
oseltamivir, and respiratory symp-
toms resolved within 5 days. He was 
discharged from the hospital but was 
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readmitted 18 days later with nasal 
congestion, cough, and high fever. 
PCR results were again positive for 
pandemic (H1N1) 2009, and the pa-
tient was successfully treated with 
oseltamivir. 
Patient 2 and probably patient 3 
acquired their infections while hospi-
talized, suggesting potential nosoco-
mial transmission. No other respira-
tory viruses were found in any of these 
patients. The viral isolates were all 
tested (LightMix for detection of in-
ﬂ  uenza A virus oseltamivir resistance 
[H274Y]; TIB MOLBIOL) for possi-
ble resistance to oseltamivir, but none 
had the resistance-implicated H274Y 
mutation in the neuraminidase gene
Shedding of seasonal inﬂ  uenza A 
virus ceases within 5–7 days during 
natural infection and during infections 
treated with neuraminidase inhibitors 
(4). Although clearing of virus after 
the ﬁ  rst infection was not documented 
in the 3 patients described here, it is 
unlikely that virus persisted between 
the 2 episodes of inﬂ  uenza since each 
of the patients fully recovered after 
speciﬁ  c antiviral drug treatment. How-
ever, we cannot rule out that patient 2 
may have never cleared the virus due 
to her immune suppression. 
As described by mathematical 
modeling (5), the 3 patients described 
were susceptible to reinfection with 
pandemic (H1N1) 2009 due to the 
high rate of community infection and 
to their incomplete immunologic pro-
tection within the period of reexpo-
sure. During the current pandemic of 
inﬂ   uenza subtype H1N1, healthcare 
workers and patients should be aware 
that symptomatic reinfection might 
occur after a ﬁ  rst episode of infection.
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Skin Lesion Caused 
by ST398 and ST1 
MRSA, Spain1
To the Editor: Human infections 
caused by methicillin-resistant Staph-
ylococcus aureus (MRSA) sequence 
type 398 (ST398) have been emerg-
ing in recent years in Europe (1,2). 
Pigs represent a common reservoir 
of MRSA ST398, and working with 
these animals may constitute a risk 
factor for MRSA carriage and pos-
sible infection (2–4). We report a case 
of human infection caused by MRSA 
ST398 in Spain.
A 12-year-old girl living close 
to a pig farm, where her father and 
mother worked, sought treatment for 
a skin lesion on her chin. Two types 
of MRSA were recovered from the 
lesion, and it resolved after topical 
treatment with mupirocin over 10 
days. MRSA isolates recovered were 
characterized by multilocus sequence 
typing (MLST) and by staphylococ-
cal cassette chromosome (SCC) mec, 
spa, and agr  typing as described 
(3). The presence of genes encoding 
Panton-Valentine leukocidin (PVL) 
(lukF/lukS), toxic shock syndrome 
toxin-1 (tsst1), and exfoliative-toxin 
A and B (eta, etb) was investigated by 
PCR (2,3). Antimicrobial susceptibil-
ity tests were carried out by using the 
VITEK-2 system (bioMérieux, Marcy 
l’Etoile, France), and mecA,  ermA, 
ermB, ermC, mrsA, tetK, tetL, tetM, 
ant(4′)-Ia,  aph(3′)-III , and aph(2′)-
aac(6′) resistance genes were stud-
ied by PCR (5). dfrK gene detection 
was performed by using primers de-
signed from the sequence FM207105 
included in GenBank (dfrK-F 5′-
GAGAATCCCAGAGGATTGGG; 
dfrK-R, 5′-CAAGAAGCTTTTCGCT
CATAAA), and the obtained ampli-
cons were sequenced for conﬁ  rma-
tion. Mutations in quinolone targets 
were determined by sequence analy-
sis of grlA and gyrA genes (6). In 
addition, MRSA isolates were typed 
by pulsed-ﬁ   eld gel electrophoresis 
(PFGE) (www.harmony-microbe.net/
microtyping.htm).
One of the clinical MRSA isolates 
recovered from the lesion and typed as 
ST398-spa-t011 showed resistance to 
tetracycline, macrolides, and lincos-
amides and harbored 5 antimicrobial 
resistance genes. The second MRSA 
strain was typed as ST1-spa-t127 and 
showed a multiresistance phenotype 
with 11 resistance genes, as well as the 
Ser80Phe and Ser84Leu amino acid 
changes in GrlA and GyrA proteins, 
respectively.
To establish the MRSA nasal 
colonization status of the patient and 
of her relatives (father, mother, and 
brother, all of whom had contact with 
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1This study was presented as a poster at 
the 19th European Congress of Clinical 
Microbiology and Infectious Diseases, 
Helsinki, Finland, 2009.